
After just one year in the role, Ambu's chairman of the board Lars Rasmussen has chosen not to run for another term at the medtech firm's general assembly in December. Rasmussen made this decision on Thursday afternoon last week, after receiving a particular email in his inbox.
A group of anonymous equity holders claimed that Rasmussen was subject to a conflict of interest by being the board chairman of both Coloplast and Ambu, after Coloplast, on the company's capital markets day, announced that it sees scopes as a potential future growth area for the firm.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app